Phathom Pharmaceuticals, Inc.
PHAT· Nasdaq
PHATPhathom Pharmaceuticals, Inc.
Filed Mar 7, 2024 · 10-K · 67 days after period end · 0000950170-24-027910
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $682.00K | — | — | — |
| Net Income | -$79.57M | -$55.05M | -$35.83M | -$53.72M |
| EPS Diluted | — | — | — |
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR
| -$1.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Mar 7, 2024 · 67 d after period end
